louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05999266: The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Official title: The Effect of Ultrasonographic Cartilage Thickness and Quadriceps/Hamstring Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rheumatoid Arthritis
Knee Pain Chronic
Muscle Loss
Cartilage Degeneration
Lead sponsor: Sisli Hamidiye Etfal Training and Research Hospital
Sponsor class: OTHER
First posted: 2023-08-21
Enrollment: 130
Sex: FEMALE
Minimum age (years): 30
Maximum age (years): 50
Standard ages: ADULT
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with Rheumatoid Arthritis

Brief summary: The knee pain status of the patients who are followed in the rheumatology special branch of the Physical Medicine and Rehabilitation Outpatient Clinic and who meet the inclusion criteria will be questioned. In patients with or without knee pain, the cartilage thickness measurement of the knee joint will be measured from 3 points by ultrasound. At the same time, Quadriceps and Hamstring muscle thickness measurements of the patients will be made from the midpoints where the muscle thickness is the highest. The physician who performed the ultrasonographic measurements of the knee pain status of the patients does not know.


Eligibility criteria: Inclusion Criteria:

* Rheumatoid Arthritis \> Diagnosed for 1 year
* -Female gender
* -The patient has been in remission or low disease activity for at least 3 months
* -Be able to ambulatory
* -No significant deformity in the lower extremity joints

Exclusion Criteria:

* Patient with active arthritis or high disease activity

  * - Significant deformity of the lower extremity joints and inability to ambulate
  * -Pregnant patient
  * - Presence of malignancy
  * - Patient with a severe psychiatric disorder and difficulty in cooperation
  * - Presence of cardiovascular and pulmonary comorbidities that will prevent exercise
  * -Male gender

Primary outcomes:
measure: Ultrasonographic Cartilage Thickness Measurement
timeFrame: through study completion, an average of 1 month
measure: Ultrasonographic Muscle Measurement Thickness Measurement
timeFrame: through study completion, an average of 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital
Study officials:
References:
Clinical trial NCT04149366: Clinical and Radiographic Evaluation of Different Thickness of Vacuum Formed Retainer (Essix Retainer) During Retention Phase After Orthodontic Treatment
Official title: Clinical and Radiographic Evaluation of Different Thickness of Vacuum Formed Retainer (Essix Retainer) During Retention Phase After Orthodontic Treatment
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Temporomandibular Joint Disorders After Using Essix Retainer
Lead sponsor: Minia University
Sponsor class: OTHER
First posted: 2019-11-04
Enrollment: 40
Sex: ALL
Minimum age (years): 15
Maximum age (years): 35
Standard ages: CHILD
ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients that have finished fixed orthodontic treatment with no signs or symptoms of temporomandibular joint disorders

Brief summary: vacuum formed retainer act as bite raiser that increase vertical dimension which may affect Tempromandibular joint and aim of this study is to perform clinical and radiographic evaluation of different thickness of vacuum formed retainer (Essix retainer) during retention phase after orthodontic treatment


Eligibility criteria: Inclusion Criteria:

* patients finished fixed orthodontic treatment with no signs or symptoms of temporomandibular joint disorders
* patients indicated for removable retainer

Exclusion Criteria:

* any systemic disease
* chronic medication uptake
* bad oral hygiene pathological conditions of temporomandibular joint

Primary outcomes:
measure: Clinical effect of retainer on temporomandibular joint
timeFrame: 9 months
measure: Radiographic effect of retainer on tempromandibular joint
timeFrame: 9 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01603966: Low Dose Aspirin Studied With the AggreGuide
Official title: Low Dose Aspirin Study With the AggreGuide
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Platelet Aggregation
Keywords: platelet
aggregation
aspirin
inhibition
reactivity
Lead sponsor: Aggredyne, Inc.
Sponsor class: INDUSTRY
First posted: 2012-05-23
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: community sample

Brief summary: This study is to determine whether the AggreGuide platelet aggregometer can discern the effect of low dose aspirin on subjects platelet aggregation using arachidonic acid as the agonist.


Eligibility criteria: Inclusion Criteria:

* adults

Exclusion Criteria:

* aspirin contraindications
* anticoagulants
* aspirin past week

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: Aggredyne, Inc.
state: Texas
Study officials:
affiliation: Aggredyne, Inc.
name: Edward R. Teitel, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04041726: Intraoperative Spillage of Bile and Gallstones During Laparoscopic Cholecysetectomy
Official title: Intraoperative Spillage of Bile and Gallstones During Laparoscopic Cholecysetectomy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cholecystitis; Gallstone
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2019-08-01
Enrollment: 30
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Results from intraoperative spillage of bile and gallstones intra abdomen during laparascopic cholecystectomy

Brief summary: 1. determine the most important factors which is responsible for the outcome post bile and gallstones spillage during laparoscopic cholecystectomy
2. the management of complications of bile and gallstones spillage

Detailed description: Laparoscopic cholecystectomy is preferred surgical treatment for symptomatic gallstones .laparscopic procedure is superior to open procedue .the incidence of gallbladder perforation and spillage of bile and gallstones has been found as high as 40% .complications and management of gall bladder perforation and spillage of gallstones and bile

Eligibility criteria: Inclusion Criteria:

* all age groups
* only laparoscopic cholecystectomy
* all types ,numbers and sizes os gall stones

Exclusion Criteria:

* open cholecystectomh
* patient refuse to enrol this study

Primary outcomes:
measure: Our purpose was to report the occurrence of complications following spilled gallstones during laparoscopic cholecystectomy at assiut university Hospital
timeFrame: Follow up complication for 6 months postoperative by abdominal ultrasound and multiple slice ct abdomen if needed
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06793826: Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea
Official title: Post-marketing Surveillance Study for the Safety of Hexaxim®, a DTaP-IPV- HB-PRP~T Vaccine Administered to Infants From 2 Months of Age in Republic of Korea
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Hepatitis B
Haemophilus Influenzae Type b Immunisation
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2025-01-27
Enrollment: 690
Sex: ALL
Minimum age (years): 2
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Infants aged 2 months or more will be recruited after vaccination with Hexaxim as per a routine healthcare visit and according to approved local product labeling, at study centers (general hospitals or clinics located in Korea). The number of subjects to enroll per site (10 sites) will be defined with each investigator

Brief summary: Primary objectives:

To investigate the incidence of adverse events occurred following administration of Hexaxim in infants from 2 months of age under routine clinical practice, as per approved indications

Detailed description: The duration of each enrolled participant's participation in the study will be up to 36 or 43 days.

Eligibility criteria: Inclusion Criteria:

* An infant aged 2 months or more on the day of enrollment
* Infant whose parent or legal representative has signed and dated the ICF
* Receipt of 1 dose of Hexaxim on the day of enrollment according to the approved local product label (regardless of vaccinated dose)

Exclusion Criteria:

* Deviational use (off-label vaccination) from the approval local product label of Hexaxim
* Previous history of enrollment in this study
* Participation at the time of study enrollment (or in the 4 weeks preceding the enrollment) or planned participation during the present study period in a clinical study investigating a vaccine, drug, medical device or medical procedure

Primary outcomes:
measure: Number of participants reporting immediate adverse events/adverse drug reactions (AEs/ADRs)
timeFrame: Within 30 minutes post-vaccination
measure: Number of participants reporting serious adverse events / adverse drug reactions (SAEs / SADRs)
timeFrame: Up to 43 days post-vaccination
measure: Number of participants reporting solicited injection site and systemic reactions
timeFrame: Up to 7 days post-vaccination
measure: Number of participants reporting unsolicited non-serious AEs/ADRs
timeFrame: Up to 28 days post-vaccination
Secondary outcomes:
Other outcomes:
Locations:
city: Cheonan
country: Korea, Republic of
facility: Investigational Site Number : 002
city: Seoul
country: Korea, Republic of
facility: Investigational Site Number : 001
Study officials:
affiliation: Sanofi Pasteur, a Sanofi Company
name: Clinical Sciences & Operations
role: STUDY_DIRECTOR
References:
Clinical trial NCT02321826: Music for Insomnia
Official title: Better Night - Better Day: a Randomized Controlled Trial of Listening to Music for Improving Insomnia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Insomnia
Sleep Disorders
Lead sponsor: University of Aarhus
Sponsor class: OTHER
Collaborators: name: Aarhus University Hospital
First posted: 2014-12-22
Enrollment: 57
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to determine the effect of listening to music on sleep quality (subjective and objective), daytime dysfunction and neurophysiological arousal in patients with insomnia.

Detailed description: Sleep problems are highly prevalent in modern society and poor sleep is associated with impaired physical and mental health with large costs for both individuals and society. Pharmacological treatment is recommended only for short-term use, and there is a need to study promising drug-free aids to improve sleep. Furthermore, the mechanisms of insomnia are not well understood. In the present project we will investigate if listening to music can improve sleep quality in persons suffering from insomnia. We will use a randomized controlled trial design including both subjective and objective measures of sleep.

Eligibility criteria: Inclusion Criteria:

* Insomnia diagnosis

Exclusion Criteria:

* Use of hypnotic medications
* Alcohol or substance abuse
* Pregnant or breastfeeding women
* Sleep apnea with an apnea hypopnea index (AHI) \>15
* Clinically significant restless leg syndrome or periodic limp movement disorder (PLMS\>25)

Primary outcomes:
measure: Change in insomnia severity
timeFrame: Baseline and three-weeks follow-up
measure: Change in subjective sleep quality
timeFrame: Baseline and three-weeks follow-up
Secondary outcomes:
measure: Change in objective sleep quality (PSG)
timeFrame: Baseline and three-weeks follow-up
measure: Change in objective sleep quality (actigraphy)
timeFrame: Baseline and three-weeks follow-up
measure: Change in daytime dysfunction
timeFrame: Baseline and three-weeks follow-up
measure: Change in physiological arousal
timeFrame: Baseline and three-weeks follow-up
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Aarhus University Hospital
Study officials:
affiliation: Center of Functionally Integrative Neuroscience, Aarhus University
name: Kira V Jespersen
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00325026: Randomized Trial Comparing Misoprostol and Foley Bulb for Labor Induction in the Preterm Gestation
Official title: Randomized Trial Comparing Misoprostol and Foley Bulb for Labor Induction in the Preterm Gestation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Premature Birth
Cervical Ripening
Keywords: Preterm gestation
Cervical ripening
Labor induction
Misoprostol
Foley bulb
Lead sponsor: University of Florida
Sponsor class: OTHER
First posted: 2006-05-11
Enrollment: 130
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the time to delivery of two different cervical ripening methods on the preterm gestation.

Detailed description: Labor induction for the preterm gestation is indicated for various maternal and fetal indications. The preterm cervix, however, is frequently not favorable for induction. Multiple methods have been evaluated in the term gestation. As these comparison studies have not included the preterm gestation, this study seeks to evaluate these two methods in terms of safety, efficacy and time to delivery.

Eligibility criteria: Inclusion Criteria:

* singleton gestation, gestational age 23-35 weeks, indication for induction

Exclusion Criteria:

* multiple gestation, non-cephalic presentation, previous uterine surgery, rupture of membranes, intrauterine fetal death

Primary outcomes:
measure: Time to vaginal delivery
Secondary outcomes:
measure: Rate of chorioamnionitis
measure: Incidence of abnormal fetal heart rate tracings
measure: Rate of postpartum hemorrhage
measure: Incidence of NICU admissions
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: Shands Hospital at the University of Florida
state: Florida
Study officials:
affiliation: University of Florida
name: Keri a Baacke, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02002026: Uterine Artery Ligation to Decrease Blood Loss With Central Placenta Previa
Official title: Uterine Artery Ligation to Minimize Blood Loss in Patients With Central Placenta Previa
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Placenta Previa Without Hemorrhage
Keywords: placenta previa, uterine artery ligation
Lead sponsor: Minia Maternity University Hospital
Sponsor class: OTHER
First posted: 2013-12-05
Enrollment: 52
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This trial will address the effect of uterine artery ligation during Cesarean section in cases with placenta previa to decrease blood loss.

Detailed description: This Study will address the effect of uterine artery ligation prior to fetal delivery during Cesarean section in cases with central placenta previa to guard against postpartum hemorrhage and to minimize blood loss.

Eligibility criteria: Inclusion Criteria:

* Placenta previa is diagnosed when the lowest placental edge is located within 5 cm of the internal os at ultrasound
* Symptomatic Placenta previa with at least one episode of bleeding
* Estimated gestational age within 28 to 40 weeks
* Maternal age \> 18 years
* Informed consent
* Social affiliation

Exclusion Criteria:

* Premature rupture of membranes
* Severe bleeding.
* Abnormal fetal heart rates.
* Pre-eclampsia, chorioamnionitis, severe chronic renal disease.

Primary outcomes:
measure: Changes in hemoglobin level
timeFrame: hemoglobin level will be done baseline and will be repeated 24 hours after delivery
Secondary outcomes:
measure: Degree of uterine contractility.
timeFrame: During CS and within 3 hours after CS
Other outcomes:
Locations:
city: Minia
country: Egypt
facility: Minia Maternity University Hospital
Study officials:
affiliation: Minia Maternity University Hospital
name: Ahmad S Sameer, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Sanad AS, Mahran AE, Aboulfotouh ME, Kamel HH, Mohammed HF, Bahaa HA, Elkateeb RR, Abdelazim AG, El-Din MAZ, Shawki HE. The effect of uterine artery ligation in patients with central placenta pevia: a randomized controlled trial. BMC Pregnancy Childbirth. 2018 Aug 29;18(1):351. doi: 10.1186/s12884-018-1989-5.
Clinical trial NCT01134926: Non Surgical Management for Uterine Residua After Pregnancy Termination, Abortion or Delivery
Official title: Phase Study Comparing Between Expectant Management and Misoprostol Treatment for Intra-uterine Residua After Pregnancy Termination, Abortion or Delivery
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Intra-uterine Residua
Keywords: Retained products of conception
residua
misoprostol
expectant management
Lead sponsor: HaEmek Medical Center, Israel
Sponsor class: OTHER
First posted: 2010-06-02
Enrollment: 23
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the study is to find out whether conservative treatment - expectant management or medical therapy using misoprostol is beneficial in the case of uterine residua, and which treatment is better.

Detailed description: Retained products of conception are estimated to occur after approximately 1-6% of pregnancies, probably more often after termination of early pregnancies then after term pregnancy. Complication are abdominal pain, infection, bleeding and for the long term - intrauterine adhesions.Blood clots in the uterine cavity can cause similar complications. The definitive treatment is curettage or hysteroscopy, both of which are carried out under general anesthesia and require an operating theater. Although expectant management and uterotonic drugs are practically used in such situation, they are not described in the literature.This study compare between the outcome of misoprostol treatment and expectant management in the case of intrauterine residua after completion of pregnancy.

Eligibility criteria: Inclusion Criteria:

* women with sonographic examination reveals suspicion of intra-uterine residua after completion of pregnancy
* intrauterine cavity, including endometrium, will be at least 15mm

Exclusion Criteria:

* the need for emergency surgical treatment (curettage)
* fever - at least 38 celsius degree
* women who had medical termination of pregnancy and the examination is after less then 2 weeks since treatment

Primary outcomes:
measure: abscence of sonographic finding in the uterine cavity
timeFrame: one week since recruitment
Secondary outcomes:
measure: Complications
timeFrame: Within one week since recruitment
measure: Woman's satisfaction
timeFrame: One week since recruitment
Other outcomes:
Locations:
city: Afula
country: Israel
facility: HaEmek medical center
Study officials:
affiliation: haemek medical center
name: yfat kadan, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01038726: Effects of Exercise and Cognitive Training on Cognitive Function in Older Adults
Official title: Neural Effects of Exercise, Cognitive, or Combined Training in AD At-Risk Elders
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Aging
Alzheimer's Disease
Keywords: Healthy Aging
Lead sponsor: The Cleveland Clinic
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
First posted: 2009-12-24
Enrollment: 108
Sex: ALL
Minimum age (years): 60
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to gain a better understanding of the effects of exercise and cognitive training on improving brain function in healthy older adults who may be at risk for developing Alzheimer's Disease.


Eligibility criteria: Inclusion Criteria:

* First or Second-degree relative of someone with Alzheimer's Disease
* Not currently engaging in regular exercise
* Able to undergo an MRI
* Fluent in English

Exclusion Criteria:

* Neurological illnesses/conditions
* Medical illness/conditions that may affect brain function
* Any unstable or severe cardiovascular disease or asthmatic condition
* Severe depressive symptoms
* Inability to walk unassisted

Primary outcomes:
measure: Brain activation patterns measured by functional MRI
timeFrame: baseline and 12 weeks
Secondary outcomes:
measure: Neuropsychological Testing
timeFrame: baseline and 12 weeks
measure: Exercise assessment
timeFrame: baseline and 12 weeks
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: The Cleveland Clinic
state: Ohio
Study officials:
affiliation: The Cleveland Clinic
name: Stephen M Rao, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: